Osteosarcoma Recurrent
8
3
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer
Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma